Outpatient versus inpatient intravenous diuretic therapy for heart failure in the United States

Affiliations

¹ Duke Clinical Research Institute, Durham, NC, USA.
² Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
³ Merck & Co., Inc., Rahway, NJ, USA.
⁴ Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, Los Angeles, CA, USA.

Free article

Stephen J Greene et al. Eur J Heart Fail. 2022 Nov.

Free article

. 2022 Nov;24(11):2199-2202.

doi: 10.1002/ejhf.2727. Epub 2022 Nov 15.

¹ Duke Clinical Research Institute, Durham, NC, USA.
² Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
³ Merck & Co., Inc., Rahway, NJ, USA.
⁴ Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, Los Angeles, CA, USA.

No abstract available

References

1. Greene SJ, Mentz RJ, Felker GM. Outpatient worsening heart failure as a target for therapy: a review. JAMA Cardiol. 2018;3:252-9.
1. DeVore AD, Allen LA, Eapen ZJ. Thinking outside the box: treating acute heart failure outside the hospital to improve care and reduce admissions. J Card Fail. 2015;21:667-73.
1. Buckley LF, Carter DM, Matta L, Cheng JW, Stevens C, Belenkiy RM, et al. Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. JACC Heart Fail. 2016;4:1-8.
1. Wierda E, Dickhoff C, Handoko ML, Oosterom L, Kok WE, de Rover Y, et al. Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: a systematic review of the literature. ESC Heart Fail. 2020;7:892-902.
1. Bhatt AS, Moscone A, McElrath EE, Varshney AS, Claggett BL, Bhatt DL, et al. Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic. J Am Coll Cardiol. 2020;76:280-8.